Jiangsu Aosaikang Pharmaceutical Co., Ltd.

12 clinical trials · Sponsor

Sort:Newest first Oldest first

◉ Watch Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Record	Firm	Date
ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (NCT07759934)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2026-03-25
ASKC200 for Knee Osteoarthritis Pain (NCT07742852)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2025-09-12
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy (NCT07109531)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2025-08-31
The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain (NCT06614608)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2024-10-01
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (NCT05306132)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2022-08-08
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole (NCT05631678)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2022-06-06
Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease (NCT07739368)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2021-09-01
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC (NCT04143607)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2019-07-23
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer (NCT03502850)	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	2017-11-30

Track Jiangsu Aosaikang Pharmaceutical Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.